InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,546.11
(
0.67%
)
US TECH 100
19,740.00
(
0.50%
)
Dow Jones
39,267.96
(
-0.10%
)
Brent Oil
87.21
(
-0.14%
)
Bitcoin
55,731.33
(
-2.20%
)
Post# of 252489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 80810

Monday, 11/28/2011 7:03:37 PM

Monday, November 28, 2011 7:03:37 PM

Post# of 252489
ABT, GSK ink deal for PLAME-antigen companion diagnostic:

http://finance.yahoo.com/news/Abbott-Expands-Agreement-GSK-prnews-2825674258.html?x=0

Under the expanded agreement, Abbott will develop a PCR test for use on the Abbott m2000rt™ instrument to screen non-small cell lung cancer tumors for the expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69% of non-small cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.

Today’s announcement is an expansion of a cancer-biomarker collaboration the two companies inked in 2009 (#msg-39511634)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up